VF
ORKA

Virtu Financial’s Oruka Therapeutics ORKA Stock Holding History

Virtu Financial’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,185
Closed -$29K – 2230
2022
Q3 		$29K Buy
+1,185
New +$33.5K ﹤0.01% 1329
2022
Q2 		– Sell
-1,990
Closed -$55K – 2169
2022
Q1 		$55K Buy
+1,990
New +$49.3K ﹤0.01% 1109
2021
Q2 		– Sell
-1,388
Closed -$61K – 2159
2021
Q1 		$61K Sell
1,388
-665
-32% -$34.9K ﹤0.01% 1411
2020
Q4 		$99K Buy
+2,053
New +$102K 0.01% 1056
2018
Q4 		– Sell
-464
Closed -$57K – 2057
2018
Q3 		$57K Buy
464
+306
+194% +$39.5K ﹤0.01% 1283
2018
Q2 		$19K Sell
158
-157
-50% -$18.4K ﹤0.01% 1868
2018
Q1 		$34K Buy
315
+206
+189% +$55.3K ﹤0.01% 1769
2017
Q4 		$32K Buy
109
+28
+35% +$8.11K ﹤0.01% 2148
2017
Q3 		$20K Buy
+81
New +$28.8K ﹤0.01% 2352

Other funds holding ORKA

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Virtu Financial's ORKA Position: Q4 2022 in Review

Virtu Financial sold out of Oruka Therapeutics (ORKA) in Q4 2022, closing a stake of 1,185 shares — an estimated $29K sold.

Virtu Financial first reported a position in ORKA in Q3 2017 and held it in 9 quarters. The position peaked at $99K in Q4 2020. 22 funds tracked by Wall St. Rank hold ORKA as of Q4 2022.

  • Virtu Financial reported no remaining Oruka Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Virtu Financial sold 1,185 Oruka Therapeutics shares in Q4 2022, an estimated $29K.
  • Virtu Financial first reported a position in Oruka Therapeutics in Q3 2017 and held it in 9 quarters.
  • Virtu Financial's Oruka Therapeutics position peaked at $99K in Q4 2020.
  • 22 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2022.

Based on Virtu Financial's 13F filing for Q4 2022, filed 15 Feb 2023.